parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in microglia (837 nCPM)	1.00
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 15	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 5553

LHFPL2 in microglia, braak-0.10 (p 0.807) → +0.03 (p 0.946)receipt 5560
LHFPL2 in dopamine neurons, braak-0.29 (p 0.457) → -0.10 (p 0.790)receipt 5561

receipt 5561: LHFPL2 in dopamine neurons, braak

power: full sample -0.18 (p 0.476, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.18 (p 0.487, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.36 (p 0.140, n 18). could be the mix.
skeptic: leave-one-out range -0.27 to -0.07, sign flips 0; without severely affected donors -0.18 (p 0.476, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LHFPL2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5560: LHFPL2 in microglia, braak

power: full sample -0.04 (p 0.861, n 18), 95% CI -0.50 to +0.43. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.807, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.04 (p 0.867, n 18). could be the mix.
skeptic: leave-one-out range -0.16 to +0.07, sign flips 3; without severely affected donors -0.04 (p 0.861, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LHFPL2 in microglia.

case closed: nothing better to follow up.

loading the receipts